Recent innovations in genotyping technology have led to the identification of genetic variants associated with increased risk of type 2 diabetes (T2D) (1-4). However, the genetic factors contributing to inter-individual variation in blood glucose levels in the general population are largely unknown. In addition to affecting metabolic health, these variants may also impact coronary heart disease (CHD) risk, for which a linear correlation between FPG and CHD mortality has been described for both diabetic and non diabetic individuals (5, 6) . Here we describe the results of a genome-wide association (GWA) study in which we aimed to identify genetic variants involved in glucose homeostasis in the general population.
We analyzed FPG as a quantitative trait in 654 normoglycemic (NG) nonobese individuals using the Illumina Infinium Human1 and Hap300 BeadArrays (Table S1 ) (1, 7). The strongest association signal was observed with SNP rs560887 (p=4×10 -7 adjusted for age, gender and body mass index (BMI) under the additive model). This SNP is part of a 17 Kb linkage disequilibrium (LD) block on chromosome 2 that encompasses the gene and 3' flanking region of the islet specific glucose-6-phosphatase related protein (IGRP, also called G6PC2
(glucose-6-phosphatase catalytic unit 2)), a glycoprotein embedded in the endoplasmic reticulum (ER) membrane (8) . Six SNPs within this LD block were genotyped in our GWA analysis. These included a non synonymous SNP (rs492594-L219V), which showed modest association with FPG (p=0.04 for rs492594-L219V, which is in low LD with rs560887 at r 2 =0.24 in CEU, according to HapMap data) and a SNP located in the 3' flanking region of G6PC2/IGRP (rs563694), which showed stronger association (p=2×10 -5 , r 2 =0.76 with rs560887) (Table S2) . We used linear regression analysis to adjust for the effect of rs560887 on all SNPs located within 100 kbp upstream and 100 kbp downstream of rs560887 that showed various levels of association with FPG (p < 0.05) and found no SNP which remained associated at significance level of 5% (Table S2 ). Imputation of genotypes using the LD structure from HapMap data (CEU population) did not identify any SNP showing potentially stronger association with FPG ( Figure 1 ). Based on these findings, we tested the association of rs560887 with FPG using a complementary subset (Table S1 ) of the French DESIR population (DESIR NG stage 2, N=3,419) and replicated our original association with FPG (β=-0.06 mmol/l per A allele; p=3×10 -8 , Table 1 ).
G6PC2/IGRP has been proposed to modulate the glycolytic pathway and eventually glucosestimulated insulin secretion by dephosphorylating glucose-6-phosphate generated by glucokinase, the beta-cell glucose sensor (9) . G6pc2 knockout mice display decreased FPG and normal insulin sensitivity (10) . Interestingly, in the DESIR NG cohort the rs560887 A allele (MAF = 0.30) that associates with decreased FPG, is also associated with a decreased fraction of erythrocyte glycosylated haemoglobin (HbA1c) (β=-0.04; p=8×10 -5 ). This reflects a better long-term glucose control, and with increased basal insulin secretion as assessed by the homeostasis model index of pancreatic beta-cell function Homa-B (β=5.46; p=2×10 -5 ), a measure derived from physiological data of FPG and fasting insulin levels (7) .
To validate these findings in different European populations, we genotyped young normoglycemic individuals from the Northern Finland Birth Cohort 86 (7) (NFBC86, N=5,073) and confirmed the association between rs560887 and decreased FPG (β=-0.07mmol/l per A allele; p=6×10 -16 ) and increased Homa-B index (β=3.79; p=6×10 -10 ). In contrast, no association was found between rs560887 and fasting insulin (p=0.5 and p=0.1, respectively) in either the French or Finnish cohorts. Similarly, neither cohort showed strong association between rs560887 and BMI (DESIR p=0.1, NFBC86 p=0.04). Adjustment for BMI did not affect the association with FPG, suggesting that the observed effect on FPG is independent of obesity-induced insulin resistance. To test this hypothesis, we studied 861 severely obese NG French children (mean age 11 ± 3 yrs) (7) . In this cohort, we still observed association between rs560887 and decreased FPG (β=-0.07 mmol/l per A allele; p=0.004) and increased Homa-B index (β=9.13; p=0.01). does not associate with FPG in European general populations (12, 13) , suggesting that the genetic determinants that regulate FPG in physiological states may be different from those that increase T2D risk. G6PC2/IGRP is homologous to two other ER proteins of the glucose-6-phosphatase family that catalyze the conversion of glucose-6-phosphate into glucose, a key enzymatic step for both gluconeogenesis and glycogenolysis (8) . In contrast to the hepatocyte specific member (G6pc1) that is highly expressed in gluconeogenic tissues but not in pancreas ( Figure S1 , upper panel), the expression of G6pc2 is restricted to islets and pancreatic betacell line MIN6 ( Figure S1 , middle panel), as it was shown in humans (14) . Since expression of G6pc2 mRNA is restricted to beta-cells in the mouse, as indicated in previous studies (14) and as confirmed in our own experiments ( Figure S1 ), rs560887 may play an important role in the early pathogenesis of this disease without contributing to overall T2D risk. For example, the rs560887 common allele (G) might alter the glucostat set-point and up-regulates FPG but the development of overt T2D may require additional compromise of the pancreatic beta-cell function.
Whether G6PC2/IGRP has the same catalytic activity as the hepatic glucose-6-phosphatase G6PC1 is a matter of debate (14) . When IGRP dephosphorylates glucose-6-phosphate, it opposes the action of the beta-cell glucose sensor glucokinase and hence moderates the glycolytic pathway and eventually glucose-stimulated insulin secretion (9) . We hypothesize that G6PC2/IGRP is part of the same glucose phosphorylation pathway that includes the glucokinase gene (GCK), responsible for the monogenic form of early onset diabetes MODY2
(15) and familial hypoglycemia-hyperinsulinemia phenotypes (16). This pathway also includes the glucokinase regulatory protein gene (GCKR). Thus, G6PC2/IGRP may antagonize the glucokinase activity in beta-cell, in a similar manner to the GCKR action as a potent inhibitor of glucokinase activity in hepatocytes (17). Recently, SNPs in both GCK (rs1799884/-30G/A) (18) and GCKR (rs1260326/P446L) (2, 19, 20) were found to modulate FPG in European population-based cohorts. To study the interaction of rs560887 with rs1260326-P446L and rs1799884/-30G/A, we analyzed their combined effect in the French DESIR cohort and observed an additive effect (interaction p=0.56) of the three SNPs on FPG (p=5×10 -21 , Figure 2 ). Individuals carrying more than four alleles associated with low FPG (10.7% of the DESIR population), show a mean 0.24 mmol/l (4.5%) decrease of FPG compared to subjects carrying only one allele ( Figure 2 ).
G6PC2 rs560887 is associated with significant reductions in both FPG and HbA1c. There is strong evidence suggesting that even small changes in blood glucose have major impact on cardiovascular morbidity and mortality (21). Meta-analyses have showed a linear relationship with no threshold between increasing FPG and CHD risk (6) , with individuals whose FPG is lower than 5.5 mM having the lowest mortality rate (5, 22) . In contrast, subjects whose FPG lies between 5.6 and 6mM, while still considered normoglycemic, show a 30% increased risk of heart failure and a 60% increased risk of nephropathy (23). In Asians, a slight reduction in FPG from 5.5 mM to 5mM is associated with a 25% reduction in CHD risk (24). Even tight blood glucose control, reflected by HbA1c between 5.1-5.6% (normal value <6.1%), is associated with a 30% higher mortality compared to a lower HbA1c (25). It was concluded that "over 80% of the population excess mortality is explained by HbA1c > 5% and occur in 70 % of the population having HbA1c between 5-6.9%" (23 
